MCID: CTR002
MIFTS: 58

Cataract

Categories: Eye diseases, Fetal diseases, Genetic diseases, Metabolic diseases, Nephrological diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Cataract

Summaries for Cataract

PubMed Health : 63 About cataracts: A cataract is an eye condition in which the lens of the eye becomes cloudy. This causes vision to worsen, making it especially difficult to see fine details clearly. Some people’s vision is only slightly affected, whereas others might lose their eyesight very quickly. How it progresses will depend on things like the exact type of cataract. The word “cataract” comes from the Greek word for “waterfall” because in the past it was believed that the blurring was caused by a fluid in the eye.Cataracts mostly affect people over 50, and the risk increases with age: About 20 out of 100 people between the ages of 65 and 74 have a cataract. And more than 50 out of 100 people over the age of 74 are affected.Cataracts are the main cause of blindness in developing countries. The number of people who go blind from cataracts is considerably lower in industrialized countries due to the availability of effective surgery. Cataract surgery involves removing the cloudy eye lens and replacing it with an artificial lens. It is one of the most common surgical procedures performed in Germany, where about 800,000 people have cataract surgery every year.

MalaCards based summary : Cataract, also known as cataracts, is related to cataract 9, multiple types and cataract 1, multiple types. An important gene associated with Cataract is IARS2 (Isoleucyl-TRNA Synthetase 2, Mitochondrial), and among its related pathways/superpathways is Protein processing in endoplasmic reticulum. The drugs gamma-Aminobutyric acid and Gabapentin have been mentioned in the context of this disorder. Affiliated tissues include Eye, eye and endothelial, and related phenotype is vision/eye.

Disease Ontology : 12 A lens disease characterized by clouding of the lens inside the eye which leads to a decrease in vision.

MedlinePlus : 43 A cataract is a clouding of the lens in your eye. It affects your vision. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery. A cataract can occur in either or both eyes. It cannot spread from one eye to the other. Common symptoms are Blurry vision Colors that seem faded Glare - headlights, lamps or sunlight may seem too bright. You may also see a halo around lights. Not being able to see well at night Double vision Frequent prescription changes in your eye wear Cataracts usually develop slowly. New glasses, brighter lighting, anti-glare sunglasses or magnifying lenses can help at first. Surgery is also an option. It involves removing the cloudy lens and replacing it with an artificial lens. Wearing sunglasses and a hat with a brim to block ultraviolet sunlight may help to delay cataracts. NIH: National Eye Institute

Wikipedia : 76 A cataract is a clouding of the lens in the eye which leads to a decrease in vision. Cataracts often... more...

Related Diseases for Cataract

Diseases in the Cataract family:

Cataract 32, Multiple Types Cataract 7
Cataract 8, Multiple Types Cataract 4, Multiple Types
Cataract 29 Cataract 42
Cataract 20, Multiple Types Cataract 1, Multiple Types
Cataract 30, Multiple Types Cataract 41
Cataract 6, Multiple Types Cataract 5, Multiple Types
Cataract 46, Juvenile-Onset Cataract 40
Cataract 10, Multiple Types Cataract 24
Cataract 3, Multiple Types Cataract 14, Multiple Types
Cataract 9, Multiple Types Cataract 2, Multiple Types
Cataract 31, Multiple Types Cataract 25
Cataract 26, Multiple Types Cataract 27
Cataract 28 Cataract 35
Cataract 22, Multiple Types Cataract 18
Cataract 21, Multiple Types Cataract 23, Multiple Types
Cataract 11, Multiple Types Cataract 33, Multiple Types
Cataract 17, Multiple Types Cataract 12, Multiple Types
Cataract 47 Cataract 34, Multiple Types
Cataract 16, Multiple Types Cataract 36
Cataract 37 Cataract 38
Cataract 39, Multiple Types Cataract 15, Multiple Types
Cataract 19, Multiple Types Cataract 43
Cataract 44 Cataract 45
Cataract 30 Cataract 33
Cataract Congenital Autosomal Dominant Cataract, Total Congenital

Diseases related to Cataract via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 947)
# Related Disease Score Top Affiliating Genes
1 cataract 9, multiple types 34.3 CRYAA GJA8
2 cataract 1, multiple types 34.2 GJA3 GJA8
3 cataract 16, multiple types 34.2 CRYAA CRYAB CRYBA1 CRYGC CRYGD CRYGS
4 cataract 30, multiple types 34.1 CRYGC CRYGD GJA3 GJA8
5 cataract 10, multiple types 34.1 CRYAB CRYBA1
6 cataract microcornea syndrome 34.0 CRYAA CRYGC CRYGD GJA8
7 cerulean cataract 34.0 CRYGD CTRCT37
8 cataract 24 34.0 CRYAA CRYBB3 CTAA2
9 cataract 29 34.0 CRYGD CTRCT29
10 cataract 25 33.9 CRYBA1 CRYGS CTRCT25 GJA8
11 cataract 14, multiple types 33.9 GJA3 GJA8
12 cataract 44 33.9 CRYAA GJA8
13 posterior polar cataract 33.9 CRYAB CRYBA1 CRYGD GJA3
14 nuclear senile cataract 33.7 CRYAA CRYGD CRYGS
15 mature cataract 33.5 CRYAA CRYGS
16 early-onset nuclear cataract 33.4 CRYAA CRYAB CRYBA1 CRYBB3 CRYGC CRYGD
17 warburg micro syndrome 31.9 CRYBB3 IARS2
18 presbyopia 30.7 CRYAA CRYGS
19 lens disease 30.4 CRYAA CRYAB CRYGD CRYGS GJA3 GJA8
20 hyperferritinemia with or without cataract 12.5
21 cataract 4, multiple types 12.5
22 cataract 2, multiple types 12.5
23 cataract 5, multiple types 12.4
24 cataract 21, multiple types 12.4
25 cataract 6, multiple types 12.4
26 cataract 3, multiple types 12.4
27 cataract 17, multiple types 12.4
28 cataract 11, multiple types 12.4
29 cataract 22, multiple types 12.4
30 cataract 40 12.4
31 cataract 23, multiple types 12.4
32 cataract 18 12.4
33 cataract 31, multiple types 12.3
34 congenital cataracts, facial dysmorphism, and neuropathy 12.3
35 cataract 8, multiple types 12.3
36 cataract 34, multiple types 12.3
37 cataract 7 12.3
38 cataract 41 12.3
39 cataract 32, multiple types 12.3
40 cataract 38 12.3
41 cataract 39, multiple types 12.3
42 myopathy, mitochondrial progressive, with congenital cataract, hearing loss, and developmental delay 12.3
43 cataract 26, multiple types 12.3
44 cataract 46, juvenile-onset 12.3
45 cataract 12, multiple types 12.3
46 microphthalmia, isolated, with cataract 1 12.3
47 cataract 19, multiple types 12.3
48 cataract 15, multiple types 12.3
49 cataract 13 with adult i phenotype 12.2
50 cataract 35 12.2

Graphical network of the top 20 diseases related to Cataract:



Diseases related to Cataract

Symptoms & Phenotypes for Cataract

MGI Mouse Phenotypes related to Cataract:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 9.23 CRYAB CRYBA1 CRYGC CRYGD CRYGS GJA3

Drugs & Therapeutics for Cataract

PubMedHealth treatment related to Cataract: 63

Some people can compensate for the vision loss, temporarily or even in the longer term, by wearing glasses or contact lenses. There are no medications for the treatment of cataracts.The only effective treatment is surgery. Cataract surgery involves removing the cloudy lens and replacing it with a new, artificial lens. The lens capsule – an elastic membrane surrounding the lens of the eye – is left in the eye during surgery. Only the inner core and the outer cortex of the lens are broken up into small pieces using ultrasound. The pieces are then sucked out of the eye through a small cut. This procedure, called phacoemulsification, is the standard technique in Germany and some other countries. Once the lens has been removed, an artificial lens is implanted into the lens capsule.Whether and when surgery is an appropriate treatment option is very much a personal decision. The extent to which vision loss is affecting someone’s life will play a very important role. Another factor to consider is the presence of other (eye) conditions, which could affect the outcome of cataract surgery.

Drugs for Cataract (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 453)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 1,Phase 2 56-12-2 119
2
Gabapentin Approved, Investigational Phase 4,Phase 1,Phase 2 60142-96-3 3446
3
Dipivefrin Approved Phase 4,Phase 3,Not Applicable 52365-63-6 3105
4
Norgestimate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 35189-28-7 6540478
5
Ethinyl Estradiol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 57-63-6 5991
6
Moxifloxacin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 354812-41-2, 151096-09-2 152946
7
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 28014-46-2
8
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-28-2 5757
9 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 979-32-8
10
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
11
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
12
Loteprednol Approved, Experimental Phase 4,Phase 3,Phase 1 82034-46-6, 129260-79-3 9865442 444025
13
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
14
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
15
Nepafenac Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 78281-72-8 151075
16
Ketorolac Approved Phase 4,Phase 3,Phase 2,Not Applicable 66635-83-4, 74103-06-3 3826
17
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 9004-61-9 53477741
18
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
19
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
20
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
21
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
22
Tobramycin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 32986-56-4 36294 5496
23
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
24
Nitric Oxide Approved Phase 4,Phase 2 10102-43-9 145068
25
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
26
Ranibizumab Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 347396-82-1 459903
27
Heparin Approved, Investigational Phase 4,Phase 2 9005-49-6 772 46507594
28
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3 113775-47-6 68602 5311068
29
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
30
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 2180-92-9, 38396-39-3 2474
31
Diclofenac Approved, Vet_approved Phase 4,Phase 1,Not Applicable 15307-86-5 3033
32
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 216974-75-3
33
Mycophenolic acid Approved Phase 4,Phase 1,Phase 2,Not Applicable 24280-93-1 446541
34
Tacrolimus Approved, Investigational Phase 4,Not Applicable 104987-11-3 445643 439492
35
Azathioprine Approved Phase 4 446-86-6 2265
36
Methotrexate Approved Phase 4,Phase 1,Phase 2 59-05-2, 1959-05-2 126941
37
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 6055-19-2, 50-18-0 2907
38
Infliximab Approved Phase 4 170277-31-3
39 tannic acid Approved Phase 4,Phase 3,Not Applicable
40
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 94-09-7, 1994-09-7 2337
41
Enoxaparin Approved Phase 4 9005-49-6 772
42
Dalteparin Approved Phase 4 9005-49-6
43
Midazolam Approved, Illicit Phase 4,Not Applicable 59467-70-8 4192
44
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
45
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
46
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
47 Homatropine Approved Phase 4 87-00-3
48
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 137-58-6 3676
49
Racepinephrine Approved Phase 4,Phase 2,Not Applicable 329-65-7 838
50
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 51-43-4 5816

Interventional clinical trials:

(show top 50) (show all 1254)
# Name Status NCT ID Phase Drugs
1 Show Improved Vision With the HOYA AF-1 Aspheric Intraocular Lens After Cataract Surgery Unknown status NCT01382641 Phase 4
2 A Study to Assess the Clinical Outcomes of Surgical Phaco Segmentation Techniques in Patients Undergoing Cataract Surgery Unknown status NCT02843594 Phase 4
3 Effect of Gabapentin on Pain of the Second Cataract Surgery Unknown status NCT02127853 Phase 4 gabapentin;placebo
4 Evaluation of Clinical Outcomes Following Implantation of a Sub-2mm Hydrophilic MICS Intraocular Lens Unknown status NCT01615861 Phase 4
5 AMO's Tecnis™ Multifocal Intraocular Lenses (Tecnis MF), Alcon's ReStor Multifocal IOL Unknown status NCT01278420 Phase 4
6 Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification Unknown status NCT01296191 Phase 4 Moxifloxacin;besifloxacin
7 Evaluation of the XEN Implant in Moderate POAG Subjects Unknown status NCT02006693 Phase 4
8 Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification Unknown status NCT01193504 Phase 4 Pred Forte;Lotemax
9 Clinical Investigation of the Modified Rayner Monofocal Aspheric 600C (With Axis Marks) Intraocular Lens Unknown status NCT02378636 Phase 4
10 Efficacy of Subtenon's Block With Olive Tipped Cannula Unknown status NCT01019018 Phase 4
11 Effect of Anti-inflammatory Topical Prednisolone, Nepafenac and Ketorolac in Intra-operative Mydriasis in Facetectomies Unknown status NCT00865540 Phase 4 prednisolone acetate 1%;ketorolac tromethamine 0.4%;nepafenac 0.1%;methylcellulose 0.5%
12 Combined Phacotube vs Phacotrabeculectomy:A Randomized Controlled Trial Unknown status NCT00273221 Phase 4
13 Effect of Posterior Corneal Toricity on Refractive Outcome of Pseudophakia Unknown status NCT01554761 Phase 4
14 ALPI vs Medical Therapy Effects on Optic Nerve Structure & Function Unknown status NCT00485238 Phase 4 Intravenous acetazolamide
15 Clinical Evaluation of Toric Intraocular Lens Made by Aurolab Unknown status NCT01396616 Phase 4
16 Efficacy Comparison Study of Steroids to Control Post-operative Inflammation Unknown status NCT01801774 Phase 4 Subtenon 20-mg triamcinolone injection;Placebo
17 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
18 IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids Unknown status NCT00744666 Phase 4 Prednisolone 1% topical eye drops
19 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
20 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
21 Long-term (3 Months) Safety of Femtosecond-laser Assisted Cataract Surgery Completed NCT02023437 Phase 4
22 A Single Centre Study to Analyze Cataract Surgery Following Femtosecond Laser-Assisted and Manual Cataract Surgery Completed NCT01769313 Phase 4
23 Aphakia Versus Pseudophakia in Children Under 2 Years Undergoing Bilateral Congenital Cataract Surgery Completed NCT01297153 Phase 4
24 Addressing of Efficacy and Safety of Femtosecond-laser Assisted Versus Manual Lens Fragmentation Procedure Completed NCT01971177 Phase 4
25 Size Progression of Macular Degeneration After Cataract Surgery Completed NCT01165801 Phase 4
26 To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery. Completed NCT00763360 Phase 4 Healon;Amvisc Plus
27 Clinical Trial on Anti-inflammatory Effect of Low-Molecular Weight Heparin in Pediatric Cataract Surgery Completed NCT00986076 Phase 4 Enoxaparin;Balanced Salt Solution
28 Comparison of Toric IOL Implantation and Opposite Clear Corneal Incision During Cataract Surgery to Correct Corneal Astigmatism Completed NCT01763151 Phase 4
29 Dexmedetomidine vs. Propofol for Cataract Surgery Completed NCT00786370 Phase 4 dexmedetomidine;Propofol;Dexemedetomidine
30 Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery Completed NCT00870103 Phase 4 Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
31 Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients Completed NCT01859702 Phase 4 Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution
32 Co-Axial Micro-Incision Versus Co-Axial Small Incision Cataract Surgery Using the Stellaris Enhancement System Completed NCT01261975 Phase 4
33 2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery Completed NCT01455233 Phase 4 besivance;vigamox
34 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema Completed NCT01546402 Phase 4 Dexamethasone Drug delivery system (Ozurdex)
35 Protein Profile of Immunoregulatory Factors in Diabetic Cataract Completed NCT01832311 Phase 4 Ketorolac
36 A Comparison of One-site and Two-site Peribulbar Anaesthesia for Cataract Surgery at Kaduna, Nigeria Completed NCT02150460 Phase 4
37 Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery Completed NCT00575380 Phase 4 AzaSite Eye Drops;Vigamox Eye Drops
38 Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care Completed NCT00698724 Phase 4 Xibrom, and Optive;Xibrom and Pred Forte
39 Laser Cataract Surgery With the Femtosecond Laser Technology Completed NCT01382823 Phase 4
40 Comparison of Topical Ketorolac 0,4% Versus Placebo in Cataract Surgery Completed NCT01542190 Phase 4 Ketorolac Tromethamine
41 Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions Completed NCT01298973 Phase 4 Viscoat;Saline
42 Clear Corneal Incisions and Arcuate Incisions Utilizing FemtoSecond Laser Technology for Cataract Surgery Completed NCT01383057 Phase 4
43 Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery Completed NCT00758199 Phase 4 Bromfenac;Moxifloxacin hydrochloride;Prednisolone Acetate
44 Influence of Two Different Preloaded Intraocular Lens (IOLs) on Posterior Capsule Opacification Completed NCT00673803 Phase 4
45 Spherical Aberration and Contrast Sensitivity in IOLs Completed NCT00576485 Phase 4
46 Comparison of Visual Outcomes and Patient Satisfaction After Cataract Surgery and Implantation of ReSTOR and ReZoom IOLs Completed NCT00366587 Phase 4
47 Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects Completed NCT00469690 Phase 4 Acular, Xibrom
48 Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery Completed NCT00348582 Phase 4 Ketorolac, Nepafenac
49 Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery. Completed NCT01244334 Phase 4 Difluprednate ophthalmic emulsion 0.05%;Prednisolone acetate 1%
50 Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery Completed NCT02137161 Phase 4 Dexamethasone+Tobramycin eye drop;Bromfenac eye drop

Search NIH Clinical Center for Cataract

Genetic Tests for Cataract

Genetic tests related to Cataract:

# Genetic test Affiliating Genes
1 Cataract 29

Anatomical Context for Cataract

MalaCards organs/tissues related to Cataract:

41
Eye, Endothelial, Testes, Retina, Heart, T Cells, Skin
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Cataract:
# Tissue Anatomical CompartmentCell Relevance
1 Eye Lens Affected by disease

Publications for Cataract

Articles related to Cataract:

(show top 50) (show all 4877)
# Title Authors Year
1
Editorial: Improvements in cataract surgery planning, technique, and outcomes. ( 30451729 )
2019
2
Impediment of selenite-induced cataract in rats by combinatorial drug laden liposomal preparation. ( 30460877 )
2019
3
Preoperative evaluation for cataract surgery. ( 30489358 )
2019
4
Cataract grading systems: a review of past and present. ( 30489359 )
2019
5
Early postoperative intraocular pressure elevation following cataract surgery. ( 30489361 )
2019
6
A Rat Eye Lens Model of Cataract Formation. ( 30535708 )
2019
7
Bilateral trifocal IOL implantation in a pediatric case of cataract following steroid-therapy for acute lymphoblastic leukemia. ( 30555958 )
2019
8
Nutritional effect on age-related cataract formation and progression. ( 30320615 )
2019
9
Different methods of chopping in cataract surgery. ( 30334824 )
2019
10
Cataract surgery and lens implantation. ( 30335627 )
2019
11
The role of perioperative nonsteroidal anti-inflammatory drugs use in cataract surgery. ( 30358619 )
2019
12
Biometry in cataract surgery: a review of the current literature. ( 30394990 )
2019
13
Comparison of the Efficacy of Sub-Tenon versus Intravitreal Triamcinolone Acetonide Injection during Cataract Surgery for Diabetic Macular Edema. ( 30041252 )
2019
14
A Missense Mutation in GJA8 Encoding Connexin 50 in a Chinese Pedigree with Autosomal Dominant Congenital Cataract. ( 29434075 )
2018
15
Enhancement and restoration of non-uniform illuminated Fundus Image of Retina obtained through thin layer of cataract. ( 29428069 )
2018
16
Evaluation of a hub-and-spoke model for the delivery of femtosecond laser-assisted cataract surgery within the context of a large randomised controlled trial. ( 29436401 )
2018
17
Ursodeoxycholic acid suppresses the formation of fructose/streptozotocin-induced diabetic cataract in rats. ( 29863796 )
2018
18
Diagnosis related group grouping study of senile cataract patients based on E-CHAID algorithm. ( 29487824 )
2018
19
Association of Cataract Surgery With Traffic Crashes. ( 29955857 )
2018
20
Postsurgical Cataract Prophylaxis With Intravitreal "Triamcinolone-Moxifloxacin" May Not Be Optimal For Preventing Endophthalmitis. ( 29944493 )
2018
21
Serum Oxidative Stress Markers in Patients with Senile Cataract and Healthy Controls. ( 29848421 )
2018
22
Mutation of IPO13 causes recessive ocular coloboma, microphthalmia, and cataract. ( 29700284 )
2018
23
Change in Nationwide Incidence of Post-Cataract Surgery Endophthalmitis: Korean Cohort Study from 2002 to 2013. ( 29953316 )
2018
24
The national and subnational prevalence of cataract and cataract blindness in China: a systematic review and meta-analysis. ( 29977532 )
2018
25
A Schlemm Canal Microstent for Intraocular Pressure Reduction in Primary Open-Angle Glaucoma and Cataract: The HORIZON Study. ( 29945799 )
2018
26
Application of 25a88MHz B-Scan Ultrasonography to Determine the Integrity of the Posterior Capsule in Posterior Polar Cataract. ( 29785304 )
2018
27
Audit of cataract surgery in Cadiz: visual outcomes and complications. ( 29433842 )
2018
28
Optical Properties Influence Visual Cortical Functional Resolution After Cataract Surgery and Both Dissociate From Subjectively Perceived Quality of Vision. ( 29450542 )
2018
29
Zinc Supplementation Ameliorates Diabetic Cataract Through Modulation of Crystallin Proteins and Polyol Pathway in Experimental Rats. ( 29756175 )
2018
30
Cataract surgery in patients with glaucoma drainage implants: the hooked tube technique. ( 29442246 )
2018
31
Outcomes of conventional phacoemulsification versus femtosecond laser-assisted cataract surgery in eyes with Fuchs endothelial corneal dystrophy. ( 29773458 )
2018
32
Markers of poor glycemic control are helpful to assess the risk of pseudophakic macular edema in diabetic cataract surgery patients. ( 29703307 )
2018
33
Femtosecond laser-assisted cataract surgery with implantation of a diffractive trifocal intraocular lens after laser in situ keratomileusis: a case report. ( 29970067 )
2018
34
Choroidal thickness changes following cataract surgery using swept source optical coherence tomography. ( 29426443 )
2018
35
Prevalence of corneal astigmatism before cataract surgery in Western Indian Population. ( 29386726 )
2018
36
Bioinformatics analysis of microarray data to explore the key genes involved in <i>HSF4</i> mutation-induced cataract. ( 29977800 )
2018
37
A Simple Method of Cataract Induction in Adult Zebrafish. ( 29437550 )
2018
38
The Routine Use of Intracameral Antibiotics to Prevent Endophthalmitis After Cataract Surgery: How Good is the Evidence? ( 29974362 )
2018
39
Hyperopic Trend after Cataract Surgery in Eyes with Fuchs' Endothelial Corneal Dystrophy. ( 29716785 )
2018
40
Comparison of immersion ultrasound and low coherence reflectometry for ocular biometry in cataract patients. ( 29977808 )
2018
41
Focal cortical cataract due to caterpillar hair migration. ( 29961989 )
2018
42
Mild Bilateral Hemorrhagic Occlusive Retinal Vasculitis Following Intracameral Vancomycin Administration in Cataract Surgery. ( 29772049 )
2018
43
Cataract surgery combined with micro-incision vitrectomy in patients with behcet's disease uveitis. ( 29954349 )
2018
44
Evaluation of the effectiveness of combined femtosecond laser-assisted cataract surgery and femtosecond laser astigmatic keratotomy in improving post-operative visual outcomes. ( 29970039 )
2018
45
HEMORRHAGIC OCCLUSIVE RETINAL VASCULITIS AFTER INTRACAMERAL VANCOMYCIN USE IN CATARACT SURGERY AFTER INTRAVENOUS EXPOSURE. ( 29474222 )
2018
46
Intravitreal Phacoemulsification Through Corneal Incision for Management of Posteriorly Dislocated Lens Material After Complicated Cataract Surgery: A New Surgical Technique. ( 29979455 )
2018
47
Outcomes of cataract surgery in eyes with ocular melanoma treated with iodine-125 brachytherapy. ( 29703285 )
2018
48
Blindness, low vision and cataract surgery outcome among adults in Hohhot of Inner Mongolia: a Rapid Assessment of Avoidable Blindness (RAAB) study. ( 29439090 )
2018
49
The role of Dexamethasone in clinical pharmaceutical treatment for patients with cataract surgery. ( 29434822 )
2018
50
The J-shape association of serum total IgE levels with age-related cataract. ( 29977816 )
2018

Variations for Cataract

ClinVar genetic disease variations for Cataract:

6 (show top 50) (show all 266)
# Gene Variation Type Significance SNP ID Assembly Location
1 IARS2 NM_018060.3(IARS2): c.2726C> T (p.Pro909Leu) single nucleotide variant Pathogenic rs587783070 GRCh38 Chromosome 1, 220143109: 220143109
2 IARS2 NM_018060.3(IARS2): c.2726C> T (p.Pro909Leu) single nucleotide variant Pathogenic rs587783070 GRCh37 Chromosome 1, 220316451: 220316451
3 EPM2A NM_005670.3(EPM2A): c.376A> G (p.Ile126Val) single nucleotide variant Conflicting interpretations of pathogenicity rs150452237 GRCh37 Chromosome 6, 146007358: 146007358
4 EPM2A NM_005670.3(EPM2A): c.376A> G (p.Ile126Val) single nucleotide variant Conflicting interpretations of pathogenicity rs150452237 GRCh38 Chromosome 6, 145686222: 145686222
5 PITX2 NM_153427.2(PITX2): c.660G> A (p.Pro220=) single nucleotide variant Benign/Likely benign rs148191851 GRCh37 Chromosome 4, 111539437: 111539437
6 PITX2 NM_153427.2(PITX2): c.660G> A (p.Pro220=) single nucleotide variant Benign/Likely benign rs148191851 GRCh38 Chromosome 4, 110618281: 110618281
7 PITX2 NM_153427.2(PITX2): c.*454C> T single nucleotide variant Benign rs6533526 GRCh38 Chromosome 4, 110617671: 110617671
8 PITX2 NM_153427.2(PITX2): c.*454C> T single nucleotide variant Benign rs6533526 GRCh37 Chromosome 4, 111538827: 111538827
9 PITX2 NM_153427.2(PITX2): c.403G> A (p.Ala135Thr) single nucleotide variant Benign/Likely benign rs77144743 GRCh37 Chromosome 4, 111539694: 111539694
10 PITX2 NM_153427.2(PITX2): c.403G> A (p.Ala135Thr) single nucleotide variant Benign/Likely benign rs77144743 GRCh38 Chromosome 4, 110618538: 110618538
11 CRYGD NM_006891.3(CRYGD): c.*12T> C single nucleotide variant Benign rs2305429 GRCh37 Chromosome 2, 208986385: 208986385
12 CRYGD NM_006891.3(CRYGD): c.*12T> C single nucleotide variant Benign rs2305429 GRCh38 Chromosome 2, 208121661: 208121661
13 CRYGD NM_006891.3(CRYGD): c.285A> G (p.Arg95=) single nucleotide variant Benign rs2305430 GRCh37 Chromosome 2, 208986637: 208986637
14 CRYGD NM_006891.3(CRYGD): c.285A> G (p.Arg95=) single nucleotide variant Benign rs2305430 GRCh38 Chromosome 2, 208121913: 208121913
15 CRYGD NM_006891.3(CRYGD): c.51T> C (p.Tyr17=) single nucleotide variant Benign rs2242074 GRCh37 Chromosome 2, 208989037: 208989037
16 CRYGD NM_006891.3(CRYGD): c.51T> C (p.Tyr17=) single nucleotide variant Benign rs2242074 GRCh38 Chromosome 2, 208124313: 208124313
17 BFSP2 NM_003571.3(BFSP2): c.1220C> A (p.Ala407Asp) single nucleotide variant Benign rs79087781 GRCh37 Chromosome 3, 133191385: 133191385
18 BFSP2 NM_003571.3(BFSP2): c.1220C> A (p.Ala407Asp) single nucleotide variant Benign rs79087781 GRCh38 Chromosome 3, 133472541: 133472541
19 PITX2 NM_153427.2(PITX2): c.459T> G (p.Ser153=) single nucleotide variant Benign/Likely benign rs35946364 GRCh37 Chromosome 4, 111539638: 111539638
20 PITX2 NM_153427.2(PITX2): c.459T> G (p.Ser153=) single nucleotide variant Benign/Likely benign rs35946364 GRCh38 Chromosome 4, 110618482: 110618482
21 MIP NM_012064.3(MIP): c.319G> A (p.Val107Ile) single nucleotide variant Benign/Likely benign rs74641138 GRCh38 Chromosome 12, 56454295: 56454295
22 MIP NM_012064.3(MIP): c.319G> A (p.Val107Ile) single nucleotide variant Benign/Likely benign rs74641138 GRCh37 Chromosome 12, 56848079: 56848079
23 HSF4 NM_001538.3(HSF4): c.123+9C> T single nucleotide variant Benign rs115335849 GRCh38 Chromosome 16, 67164943: 67164943
24 HSF4 NM_001538.3(HSF4): c.123+9C> T single nucleotide variant Benign rs115335849 GRCh37 Chromosome 16, 67198846: 67198846
25 PITX2 NM_153427.2(PITX2): c.480A> T (p.Ser160=) single nucleotide variant Conflicting interpretations of pathogenicity rs141176394 GRCh37 Chromosome 4, 111539617: 111539617
26 PITX2 NM_153427.2(PITX2): c.480A> T (p.Ser160=) single nucleotide variant Conflicting interpretations of pathogenicity rs141176394 GRCh38 Chromosome 4, 110618461: 110618461
27 UPF3B NM_080632.2(UPF3B): c.758T> C (p.Ile253Thr) single nucleotide variant Uncertain significance rs754982440 GRCh37 Chromosome X, 118975088: 118975088
28 UPF3B NM_080632.2(UPF3B): c.758T> C (p.Ile253Thr) single nucleotide variant Uncertain significance rs754982440 GRCh38 Chromosome X, 119841125: 119841125
29 CRYGD NM_006891.3(CRYGD): c.295A> G (p.Arg99Gly) single nucleotide variant Uncertain significance rs886055527 GRCh37 Chromosome 2, 208986627: 208986627
30 CRYGD NM_006891.3(CRYGD): c.295A> G (p.Arg99Gly) single nucleotide variant Uncertain significance rs886055527 GRCh38 Chromosome 2, 208121903: 208121903
31 CRYGD NM_006891.3(CRYGD): c.252+10T> A single nucleotide variant Likely benign rs200111275 GRCh37 Chromosome 2, 208988826: 208988826
32 CRYGD NM_006891.3(CRYGD): c.252+10T> A single nucleotide variant Likely benign rs200111275 GRCh38 Chromosome 2, 208124102: 208124102
33 CRYGD NM_006891.3(CRYGD): c.10-7C> G single nucleotide variant Likely benign rs189582567 GRCh37 Chromosome 2, 208989085: 208989085
34 CRYGD NM_006891.3(CRYGD): c.10-7C> G single nucleotide variant Likely benign rs189582567 GRCh38 Chromosome 2, 208124361: 208124361
35 CRYGD NM_006891.3(CRYGD): c.-40C> T single nucleotide variant Likely benign rs113618781 GRCh37 Chromosome 2, 208989237: 208989237
36 CRYGD NM_006891.3(CRYGD): c.-40C> T single nucleotide variant Likely benign rs113618781 GRCh38 Chromosome 2, 208124513: 208124513
37 CRYGD NM_006891.3(CRYGD): c.482A> G (p.Asn161Ser) single nucleotide variant Uncertain significance rs760434926 GRCh37 Chromosome 2, 208986440: 208986440
38 CRYGD NM_006891.3(CRYGD): c.482A> G (p.Asn161Ser) single nucleotide variant Uncertain significance rs760434926 GRCh38 Chromosome 2, 208121716: 208121716
39 CRYGD NM_006891.3(CRYGD): c.252+7A> G single nucleotide variant Likely benign rs185860020 GRCh37 Chromosome 2, 208988829: 208988829
40 CRYGD NM_006891.3(CRYGD): c.252+7A> G single nucleotide variant Likely benign rs185860020 GRCh38 Chromosome 2, 208124105: 208124105
41 CRYGD NM_006891.3(CRYGD): c.130A> G (p.Met44Val) single nucleotide variant Benign/Likely benign rs61731517 GRCh37 Chromosome 2, 208988958: 208988958
42 CRYGD NM_006891.3(CRYGD): c.130A> G (p.Met44Val) single nucleotide variant Benign/Likely benign rs61731517 GRCh38 Chromosome 2, 208124234: 208124234
43 CRYGD NM_006891.3(CRYGD): c.-80A> C single nucleotide variant Uncertain significance rs886055528 GRCh37 Chromosome 2, 208989277: 208989277
44 CRYGD NM_006891.3(CRYGD): c.-80A> C single nucleotide variant Uncertain significance rs886055528 GRCh38 Chromosome 2, 208124553: 208124553
45 CRYGD NM_006891.3(CRYGD): c.499C> T (p.Leu167=) single nucleotide variant Likely benign rs774626835 GRCh37 Chromosome 2, 208986423: 208986423
46 CRYGD NM_006891.3(CRYGD): c.499C> T (p.Leu167=) single nucleotide variant Likely benign rs774626835 GRCh38 Chromosome 2, 208121699: 208121699
47 CRYGD NM_006891.3(CRYGD): c.376G> A (p.Val126Met) single nucleotide variant Likely benign rs150318966 GRCh37 Chromosome 2, 208986546: 208986546
48 CRYGD NM_006891.3(CRYGD): c.376G> A (p.Val126Met) single nucleotide variant Likely benign rs150318966 GRCh38 Chromosome 2, 208121822: 208121822
49 CRYGD NM_006891.3(CRYGD): c.-39C> T single nucleotide variant Likely benign rs765407471 GRCh37 Chromosome 2, 208989236: 208989236
50 CRYGD NM_006891.3(CRYGD): c.-39C> T single nucleotide variant Likely benign rs765407471 GRCh38 Chromosome 2, 208124512: 208124512

Copy number variations for Cataract from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 86882 14 67000000 106368585 Copy number cataract
2 89231 15 17000000 100338915 Copy number cataract
3 106728 17 1 11200000 Copy number cataract

Expression for Cataract

Search GEO for disease gene expression data for Cataract.

Pathways for Cataract

Pathways related to Cataract according to KEGG:

37
# Name Kegg Source Accession
1 Protein processing in endoplasmic reticulum hsa04141

GO Terms for Cataract

Cellular components related to Cataract according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gap junction GO:0005921 8.96 GJA3 GJA8
2 connexin complex GO:0005922 8.62 GJA3 GJA8

Biological processes related to Cataract according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lens development in camera-type eye GO:0002088 9.35 CRYAB CRYBA1 CRYGD CRYGS GJA8
2 visual perception GO:0007601 9.23 CRYAA CRYBA1 CRYBB3 CRYGC CRYGD GJA3
3 negative regulation of intracellular transport GO:0032387 9.16 CRYAA CRYAB

Molecular functions related to Cataract according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of eye lens GO:0005212 9.17 CRYAA CRYAB CRYBA1 CRYBB3 CRYGC CRYGD
2 gap junction channel activity GO:0005243 8.96 GJA3 GJA8

Sources for Cataract

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....